Prematurity Prevention & Louisiana Medicaid: Progress to date and a path forward

Pooja Mehta, MD MSHP
Director of Maternal and Women’s Health Policy
Medical Director, Louisiana Perinatal Quality Collaborative
LSUHSC-LDH Consortium for Health Transformation
Assistant Professor, LSUHSC Schools of Medicine and Public Health
Objectives

• Model potential format and forum for future Quality Committee meetings
• Present plan-stratified data/action on Quality strategy measures, emphasizing incentivized measures (process)
• Present and collect feedback on preliminary evaluation of population health impact (outcomes)
• Present subcommittee/Committee feedback obtained prior to this meeting
• Facilitate discussion on optimizing improvement in next Performance Improvement Project cycle, providing medical provider input to plans
BACKGROUND

Louisiana Medicaid Prematurity Prevention Performance Improvement Project
Why focus on preterm birth? Why 17-hydroxyprogesterone (17-P)?

- Half of infant mortality occurs in babies born at <32 weeks, significant racial disparities
- Preterm neonates = half annual infant hospitalization costs
- 17-P is one of few evidence-based interventions for prevention:
  - 2 2003 RCTs inform recommendations
  - 33% reduction in those with a prior spontaneous preterm birth (weekly admin 16–36w)
  - Works best in women w/ prior PTB before 34w

Data source: Louisiana Vital Records, courtesy Lyn Kieltyka
Quality strategy in 2014 contract included shared targets for population health improvement

16 incentivized measures in contract extension effective 2/1/18

Medicaid expansion 7/1/2016

Commitment to broader payment and system transformation

Provider/public health champions focused on infant mortality

All managed care plans participate in a collaborative Prematurity Performance Improvement Project
Medicaid Performance Improvement Projects (PIPs)

- Purpose: achieve and sustain demonstrable improvement in quality and appropriateness of care services over time
- Required of managed care organizations (MCOs) by CMS
- Plans engaged in PIPs with support from an External Quality Review Organization
- Collaborative PIP process: all plans work on same measures
- 2 PIPs: 1) prematurity prevention, 2) ADHD
- 3rd PIP: in development with goal to focus on behavioral health
Financial incentives for quality improvement

For CY 2017 reported in 2018

- 9 financially-incentivized quality measures
  - Some HEDIS/CMS/CHIPRA
  - 1 homegrown
- Some measures subject to a $250,000 penalty for failure to meet performance target

For CY 2018 reported in 2019

- 16 financially-incentivized quality measures
  - 13 HEDIS, 2 CAHPS
  - 1 homegrown
- 1% of gross revenue withheld for quality outcomes (1/16 per measure)
- Plans must meet target (national 50th percentile or LDH established target) or 2 points over the plan’s prior year performance to “earn back” the 1%
Incentivized measure selection

- Contract extension: continuation of a “home-grown” measure for initiation of injectable progesterone (17-P) for recurrent preterm birth prevention

| #01 (PTB) $$ | Initiation of Injectable Progesterone for Preterm Birth Prevention | The percentage of women 15-45 years of age with evidence of a previous preterm singleton birth event (24-36 weeks completed gestation) who received one or more progesterone injections between the 16th and 24th week of gestation for deliveries during the measurement year | State-Section V | None | Children’s and Maternal Health | Perinatal and Reproductive Health |
What have we achieved?

2010: Coverage of compounded progesterone

2014: Coverage of Makena

2014-15: PIP launch
• Baseline measurement period

• Birth Outcomes Initiative focused on 39w delivery
• LAMMICO CME
• March of Dimes CME in high risk regions
• Coverage of Alere/Optum home administration
• High Risk Pregnancy Registry made available to MCOs

2015-16: Addressing barriers to 17-P

• Interim PIP measurement
• Intervention period

• LA ACOG engagement
• Medicaid Ordering & Billing Guide
• Reimbursement rate increase compounded 17P

2017-19: Data-driven improvement

• PIP re-measurement period
• PIP report submission 6/2018

• Perinatal Commission contacted outlier providers
• Launch of Perinatal Quality Collaborative
• Institute of Healthcare Improvement style QI training

• Final reports 6/2019

2017-19: Data-driven improvement
“The Collaborative PIP aims...”

“...to decrease the preterm birth rate by implementing a robust set of health plan, member and provider interventions to improve rates of the following performance indicators:”

1. **Progesterone measure:**
   - women with a prior preterm birth who receive 1 or more progesterone injections between 16-21 weeks gestation (changed to 16-24 in 2016)

2. **STI screening** during pregnancy for: a) Chlamydia b) HIV c) Syphilis

3. **Postpartum visit** attendance

4. **Contraceptive Measure**-
   - % of postpartum women who:
     - Adopt use of a most effective method, (i) female sterilization or (ii) Long-Acting Reversible Contraception (LARC)
     - Adopt use of a moderately effective method of contraception, i.e., use of injectables, oral pills, patch, ring or diaphragm.
Components of a 17-P centered prematurity prevention strategy

- **Selection of target population**
  - Currently pregnant members with any prior preterm birth <37w
  - Maternal age from 11y to 50 years

- **Identification of members**
  - Vital record information on gestational age and matched with all women and children ever enrolled in Medicaid via agreement between Medicaid and Office of Public Health
  - Registry provided to Medicaid fiscal intermediary: parses list according to plan enrollment and distributes to MCOs
  - Providers submit “Notification of Pregnancy” to MCOs
Components of a 17-P centered prematurity prevention strategy

• Measure validation
  – MCOs report most Quality Performance Measures to the National Committee for Quality Assurance (NCQA)
  – “Home grown” measure validated by ULM and External Quality Review Organization

• Setting of targets
  – Contractual target of 20.65% (reported in 2018 for CY 2018) initiation rate in women with prior preterm birth, based on best performance reported to LDH by any MCO for the prior measurement year
  – PIP can set different target for collaborative goal

• Evaluation
  – Primary data from MCOs shared in plan Performance Improvement Project, validated where possible
  – Global evaluation data from Medicaid claims data
Example plan interventions to date

- High risk pregnancy registry paired with internal registries to identify high-risk members (5)
- Case management contact and support for high-risk members (5)
- Provider financial incentives for notification of pregnancy forms, administering 17P injections (1)
- Patient financial incentives for receiving 17P injections (1)
- Home administration of 17P via Optum (5)
- High-risk members get a phone to promote communication (1)
- Community case management/CHW support for members who drop out of care (2)
- Provider visits to review quality outcomes and personal metrics (2)
Louisiana Medicaid Prematurity Prevention Performance Improvement Project

PROCESS OUTCOMES ON KEY MEASURES
Louisiana Medicaid Initiation of Injectable Progesterone Measure 2013-2016—Total

Statewide rates (MCO+FFS) calculated by ULM. CY2016 specifications include progesterone injections between weeks 16 and 24, while previous years included injections between weeks 16 and 21. For comparison, CY2016 results for injections between weeks 16 and 21 were 14.3%.
All rates were calculated by ULM, with the exception of plan-reported rates for ACLA, Healthy Blue, and UHC for CY2016. Also, please note that CY2016 specifications include progesterone injections between weeks 16 and 24, while previous years included injections between weeks 16 and 21.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Aetna</td>
<td>9.0%</td>
<td>14.3%</td>
<td></td>
<td>14.3% (19/133)</td>
</tr>
<tr>
<td>AmeriHealth Caritas of Louisiana</td>
<td>5.9%</td>
<td>8.6%</td>
<td>11.2%</td>
<td>20.7% (83/402)</td>
</tr>
<tr>
<td>Healthy Blue</td>
<td>4.9%</td>
<td>8.2%</td>
<td>12.3%</td>
<td>17.6% (109/621)</td>
</tr>
<tr>
<td>Louisiana Healthcare Connections</td>
<td>3.8%</td>
<td>7.4%</td>
<td>8.6%</td>
<td>13.8% (142/1028)</td>
</tr>
<tr>
<td>United Healthcare of Louisiana</td>
<td>5.1%</td>
<td>7.4%</td>
<td>9.3%</td>
<td>18.0% (168/933)</td>
</tr>
</tbody>
</table>
All rates were calculated by ULM, with the exception of plan-reported rates for ACLA, Healthy Blue, and UHC for CY2016. Also, please note that CY2016 specifications include progesterone injections between weeks 16 and 24, while previous years included injections between weeks 16 and 21.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Aetna</td>
<td>9.0%</td>
<td>14.3%</td>
<td>9.0%</td>
<td>14.3% (19/133)</td>
</tr>
<tr>
<td>AmeriHealth Caritas of Louisiana</td>
<td>5.9%</td>
<td>8.6%</td>
<td>11.2%</td>
<td>20.7% (83/402)</td>
</tr>
<tr>
<td>Healthy Blue</td>
<td>4.9%</td>
<td>8.2%</td>
<td>12.3%</td>
<td>17.6% (109/621)</td>
</tr>
<tr>
<td>Louisiana Healthcare Connections</td>
<td>3.8%</td>
<td>7.4%</td>
<td>8.6%</td>
<td>13.8% (142/1028)</td>
</tr>
<tr>
<td>United Healthcare of Louisiana</td>
<td>5.1%</td>
<td>7.4%</td>
<td>9.3%</td>
<td>18.0% (168/933)</td>
</tr>
</tbody>
</table>
Regional Rates (MCO+FFS) calculated by ULM.
## Louisiana Medicaid Initiation of Injectable Progesterone Measure 2013-2016 – By Region

![Regional Rates (MCO+FFS) calculated by ULM.](chart.png)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Region 1 - New Orleans</td>
<td>4.6%</td>
<td>8.0%</td>
<td>12.0%</td>
<td>18.0% (83/461)</td>
</tr>
<tr>
<td>Region 2 - Baton Rouge</td>
<td>2.2%</td>
<td>6.1%</td>
<td>8.1%</td>
<td>15.0% (68/454)</td>
</tr>
<tr>
<td>Region 3 - Thibodaux</td>
<td>7.4%</td>
<td>7.3%</td>
<td>11.4%</td>
<td>18.9% (54/286)</td>
</tr>
<tr>
<td>Region 4 - Lafayette</td>
<td>11.8%</td>
<td>10.3%</td>
<td>11.8%</td>
<td>17.2% (76/443)</td>
</tr>
<tr>
<td>Region 5 - Lake Charles</td>
<td>2.0%</td>
<td>3.5%</td>
<td>4.4%</td>
<td>13.3% (26/195)</td>
</tr>
<tr>
<td>Region 6 - Alexandria</td>
<td>2.8%</td>
<td>4.7%</td>
<td>10.1%</td>
<td>9.1% (19/208)</td>
</tr>
<tr>
<td>Region 7 - Shreveport</td>
<td>3.8%</td>
<td>7.4%</td>
<td>11.7%</td>
<td>21.1% (103/488)</td>
</tr>
<tr>
<td>Region 8 - Monroe</td>
<td>3.3%</td>
<td>5.6%</td>
<td>8.4%</td>
<td>16.7% (53/317)</td>
</tr>
<tr>
<td>Region 9 - Mandeville</td>
<td>2.8%</td>
<td>4.8%</td>
<td>7.1%</td>
<td>14.3% (44/308)</td>
</tr>
<tr>
<td>Other</td>
<td>3.5%</td>
<td>3.2%</td>
<td>6.2%</td>
<td>13.5% (12/89)</td>
</tr>
</tbody>
</table>

Regional Rates (MCO+FFS) calculated by ULM.
Louisiana Medicaid Initiation of Injectable Progesterone Measure 2013-2016 – By Race

By-Race Rates (MCO+FFS) calculated by ULM.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>White</td>
<td>4.7%</td>
<td>7.0%</td>
<td>9.2%</td>
<td>17.0% (160/942)</td>
</tr>
<tr>
<td>Black</td>
<td>4.6%</td>
<td>6.7%</td>
<td>10.1%</td>
<td>16.4% (337/2,052)</td>
</tr>
<tr>
<td>Hispanic</td>
<td>6.4%</td>
<td>4.3%</td>
<td>8.9%</td>
<td>11.5% (9/78)</td>
</tr>
<tr>
<td>Other</td>
<td>5.0%</td>
<td>6.3%</td>
<td>10.8%</td>
<td>18.5% (15/81)</td>
</tr>
<tr>
<td>Unknown</td>
<td>4.7%</td>
<td>7.6%</td>
<td>7.6%</td>
<td>17.7% (17/96)</td>
</tr>
</tbody>
</table>
Chlamydia Screening During Pregnancy for 2016 Measurement Year – By Plan

- Aetna: 78.3%
- AmeriHealth Caritas of Louisiana: 89.5%
- Healthy Blue: 85.5%
- Louisiana Healthcare Connections: 85.6%
- United Healthcare of Louisiana: 86.2%
- Healthy Louisiana: 85.5%
- Average: 85.5%
Syphilis Screening During Pregnancy for 2016 Measurement Year – By Plan

- Aetna: 80.5%
- AmeriHealth Caritas of Louisiana: 89.3%
- Healthy Blue: 84.6%
- Louisiana Healthcare Connections: 85.4%
- United Healthcare of Louisiana: 87.1%
- Healthy Louisiana Average: 85.8%
Louisiana Medicaid Postpartum Care Rates During 2013-2016 Measurement Years

Statewide MCO Rates calculated by plans for HEDIS Postpartum Care measure.

<table>
<thead>
<tr>
<th>Year</th>
<th>Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>CY 2013</td>
<td>30.7%</td>
</tr>
<tr>
<td>CY 2014</td>
<td>46.7%</td>
</tr>
<tr>
<td>CY 2015</td>
<td>60.2%</td>
</tr>
<tr>
<td>CY 2016</td>
<td>63.8%</td>
</tr>
</tbody>
</table>
Louisiana Medicaid Postpartum Care Rate 2013-2016 – By Plan

Rates Reported by Healthy Louisiana Plans.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Aetna</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AmeriHealth Caritas of Louisiana</td>
<td>32.4%</td>
<td>43.1%</td>
<td>64.7%</td>
<td>57.1%</td>
</tr>
<tr>
<td>Community Health Solutions</td>
<td>29.0%</td>
<td>29.6%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Healthy Blue</td>
<td>56.4%</td>
<td>55.8%</td>
<td>62.0%</td>
<td>65.1%</td>
</tr>
<tr>
<td>Louisiana Healthcare Connections</td>
<td>41.4%</td>
<td>50.2%</td>
<td>58.2%</td>
<td>64.9%</td>
</tr>
<tr>
<td>United Healthcare of Louisiana</td>
<td>55.0%</td>
<td>55.0%</td>
<td>58.7%</td>
<td>64.8%</td>
</tr>
</tbody>
</table>

Rates Reported by Healthy Louisiana Plans.
Louisiana Medicaid Most/Moderately Effective Contraceptive Care Rates for 2016 Measurement Year – 60 Days, By Plan

Healthy Louisiana Rates calculated by ULM for women aged 15-44 years. Based on CMS Adult and CHIPRA Core Set Specifications. Rates are reported as within 60 days post-delivery.

- Aetna: 46.0%
- AmeriHealth Caritas of Louisiana: 48.3%
- Healthy Blue: 50.4%
- Louisiana Healthcare Connections: 50.8%
- United Healthcare of Louisiana: 49.6%
- Healthy Louisiana Average: 49.6%
Louisiana Medicaid LARC Contraceptive Care Rates for 2016 Measurement Year – 3 Days and 60 Days, By Plan

Healthy Louisiana Rates calculated by ULM for women aged 15-44 years. Based on CMS Adult and CHIPRA Core Set Specifications.

- Aetna: 12.6% 1.5%
- AmeriHealth Caritas of Louisiana: 12.0% 2.4%
- Healthy Blue: 12.4% 1.8%
- Louisiana Healthcare Connections: 13.0% 1.7%
- United Healthcare of Louisiana: 10.3% 1.3%
- Healthy Louisiana Average: 11.9% 1.7%
Healthy Louisiana Rates calculated by ULM for women aged 15-44 years. Based on CMS Adult and CHIPRA Core Set Specifications. Rates are reported as within 60 days post-delivery.
Louisiana Medicaid LARC Contraceptive Care Rates for 2016 Measurement Year – 3 Days and 60 Days, By Race

Healthy Louisiana Rates calculated by ULM for women aged 15-44 years. Based on CMS Adult and CHIPRA Core Set Specifications.

<table>
<thead>
<tr>
<th>Race</th>
<th>60-Day</th>
<th>3-Day</th>
</tr>
</thead>
<tbody>
<tr>
<td>White</td>
<td>10.7%</td>
<td>0.6%</td>
</tr>
<tr>
<td>Black</td>
<td>12.4%</td>
<td>2.5%</td>
</tr>
<tr>
<td>Hispanic</td>
<td>16.5%</td>
<td>1.4%</td>
</tr>
<tr>
<td>Other</td>
<td>10.5%</td>
<td>0.3%</td>
</tr>
<tr>
<td>Unknown</td>
<td>15.4%</td>
<td>2.5%</td>
</tr>
<tr>
<td>Total</td>
<td>11.9%</td>
<td>1.7%</td>
</tr>
</tbody>
</table>
IMPACT ON POPULATION HEALTH?
Louisiana Medicaid Prematurity Rates <37 Weeks During 2013-2016 Among Total Medicaid Singleton Births

Statewide Rates (MCO+FFS) calculated by ULM for women having a preterm (<37 weeks) singleton birth among total Medicaid paid singleton births.

- CY 2013: 12.2%
- CY 2014: 10.9%
- CY 2015: 11.0%
- CY 2016: 11.7%
So...has anyone succeeded? Yes!
How did they achieve this?
Do we need to revisit our approach...to our aim?

• Ohio Perinatal Quality Collaborative (providers)
  – Early access to prenatal care (postpartum education on progesterone in prior pregnancy)
  – Early recognition of prior preterm birth
  – CL screening protocols
  – Expedite progesterone supplementation
  – Customize care to start and maintain progesterone

• Ohio Medicaid Managed Care Performance Improvement Project
  – Continuous insurance coverage
  – Timely & accurate identification of progesterone candidate thru meaningful use of data
  – Timely access to progesterone (progesterone point person in MCO, no prior authorizations, reimbursement clarity)
  – Patient engagement & education
  – Build trust with payers, providers, patients (common communication materials branded through OPQC)
  – Social and administrative barriers
Louisiana Medicaid Prematurity Rates <32 Weeks During 2013-2016 for Women Having a Previous Preterm Birth <37 Weeks

Statewide Rates (MCO+FFS) calculated by ULM for women having an early preterm (<32 weeks) singleton birth who had a previous preterm singleton birth (<37 weeks). Restricted to women eligible for Medicaid during month of delivery.

<table>
<thead>
<tr>
<th>CY</th>
<th>Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>CY 2013</td>
<td>5.4%</td>
</tr>
<tr>
<td>CY 2014</td>
<td>5.4%</td>
</tr>
<tr>
<td>CY 2015</td>
<td>5.1%</td>
</tr>
<tr>
<td>CY 2016</td>
<td>4.7%</td>
</tr>
</tbody>
</table>
CY2016 Louisiana Medicaid Prematurity Rates <37 Weeks Among All Medicaid Births and <32 Weeks for Women Having a Previous Preterm Birth – By Region

- New Orleans: 12.1% (12.0%), 6.7% (4.2%)
- Baton Rouge: 12.0% (4.2%), 3.0%
- Thibodaux: 10.7% (5.2%), 3.0%
- Lafayette: 11.7% (3.8%), 2.0%
- Lake Charles: 10.6% (2.0%), 5.5%
- Alexandria: 12.3% (3.5%), 2.0%
- Shreveport: 14.3% (5.5%), 3.5%
- Monroe: 12.8% (6.5%), 3.0%
- Mandeville: 10.0% (4.7%), 4.7%
- Other: 8.8% (7.4%),
- Total: 11.7% (4.7%)

Note: The first number in parentheses is the <37 Weeks rate, and the second number is the <32 Weeks Prior PTB rate.
REFRAMING FOR A YEAR OF COLLABORATIVE IMPROVEMENT
Postpartum Contraceptive Uptake & Case Management

A study of 7,120 randomly selected, Medicaid-covered live births in North Carolina between 2008-2010, compared 3-month contraceptive use among women who:

- received prenatal and postpartum care coordination
- received only prenatal care coordination
- received no maternity care coordination

Findings: Women who had both prenatal and postpartum care coordination had a 19 percentage point higher rate of contraceptive use at 3-months postpartum than those who received no care coordination or received only prenatal care coordination (Rutledge et al 2016).

By July 2019:

Reduce Preterm Birth <37w by x% in women with a prior preterm birth and Preterm Birth <32w by x% in women with a prior preterm birth in LA Medicaid population

a) Improve the initiation of progesterone between 16-24 weeks gestational age for the high-risk maternity Medicaid population (prior spontaneous preterm birth) from 16% to y%

(y) 50% rate initiation
17P = 1133 women = 374 fewer PTB = $12,089,550 saved!

(x) 20% reduction in recurrent preterm birth <32w = 37 fewer preterm births <32w = 111/3249 women more on progesterone if prior PTB (or ASA if they delivered early because of preeclampsia!)
Feedback from Maternity Care (OB/MFM) Subcommittee

LA Medicaid Expansion beginning July 1, 2016, provides coverage to pregnant women with household incomes up to 133% of the FPL.

LA Medicaid covers both Makena and 17-P, at no cost to Medicaid patients.

Elimination of prior authorization requirements for Makena/17-P in LA Medicaid MCOs.

LA Medicaid MCOs offer coverage of the drug as both pharmacy & medical benefit.

Insurance and pricing barriers:
- High rates of uninsurance in Louisiana
- Variable insurance coverage of Makena & 17-P
- Prior authorization requirements
- Variable coverage of the drug as medical benefit vs. pharmacy benefit

Supply chain barriers:
- 17P must be ordered through a compounding pharmacy
- Makena is only available through certain specialty pharmacies
- Many providers choose not to stock Makena due to its high price

Creation of the 17-P Louisiana Ordering and Billing Summary distributed by MCOs, ACOG

Member Adherence barriers:
- Difficulty adhering to weekly injections
- Transportation
- Fear of injections
- Trust in health system
- Perception of risk
- Provider practice organization and behavior

LA Medicaid MCOs cover home administration of injectable progesterone.
• Can we explicitly aim to reduce disparities as well as improve outcomes?
• Can next round of interventions involve more direct involvement with providers?
  – High risk pregnancy navigators at practice level with MCO financial support? Consistent risk stratification?
  – Assistance with provider tracking of clients/members eligible for intervention?
  – Can MCOs support integrated education campaigns for providers and community members?
  – Integrated MCO approach to “outlier” providers and regions?
Further questions for discussion

• Which interventions have been most and least useful to date?

• PIP as an opportunity for partnered improvement work between plans and providers...What do plans and providers need from each other?
  – Mixed quality reports
  – Practice engagement and transformation
  – Management of outliers

• What is the role of member engagement in this effort—how, when, by whom?
Louisiana Medicaid Prematurity Prevention Performance Improvement Project

THANK YOU! FEEDBACK?
APPENDIX: SUPPLEMENTARY MATERIAL PRESENTED TO PREMATURITY PIP
• Providers who provided care for >5 pregnant women with a prior preterm, singleton live birth at least once between 16-24 weeks gestation, with <10% of linked patients with prior preterm birth receiving at least one progesterone injection
  – Average # eligible women served by provider: 11 (range 6 - 45 women)
  – Median # patient visits among women with prior preterm birth: 20 (range 14-162 visits)
  – If women have seen multiple providers during that timeframe, the 1 with the most visits is considered “linked”
• Resulted in 44 providers and each was called by chair of LA Perinatal Commission
Findings on progesterone

• Two randomized controlled trials in 2003 found that women with prior preterm birth who were randomized to receive progesterone (17 P) had decreased recurrent preterm births by 33% as well as decreased neonatal morbidity.

• Randomized controlled trials also have found that universal transvaginal cervical length screening at 18-24 weeks of gestation and administration of vaginal progesterone for those with a cervical length ≤25 mm has shown a significant reduction in preterm births (Romero et al 2016).

• Retrospective cohort studies do not address confounders.
Findings on risk stratification for case management

- Modifiable risk factors that closely predicted preterm birth were studied in a retrospective cohort of the North Carolina Medicaid population between September 2011–September 2012 (N = 15,428).

<table>
<thead>
<tr>
<th>Strongest Risk Factors</th>
<th>Other Significant Risk Factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>• previous preterm birth</td>
<td>• smoking during pregnancy</td>
</tr>
<tr>
<td>• hypertension</td>
<td>• asthma</td>
</tr>
<tr>
<td>• cervical insufficiency</td>
<td>• other chronic conditions (e.g., thyroid disease and anemia)</td>
</tr>
<tr>
<td>• diabetes</td>
<td>• history of a low birth weight infant or fetal death/second trimester loss</td>
</tr>
<tr>
<td>• renal disease</td>
<td></td>
</tr>
<tr>
<td>• multi-fetal gestation</td>
<td></td>
</tr>
</tbody>
</table>
In a retrospective cohort study using vital statistics birth records from 2006 to 2011 in Ohio (N=393,441), low pre-pregnancy BMI, short inter-pregnancy intervals of <6/< 12 months (from birth of last pregnancy to conception in current pregnancy), and inadequate pregnancy weight gain (according to Institute of Medicine guidelines), predicted preterm birth, comprising 25% of preterm births in this cohort (Lengyel 2017)
Findings on “case management”

- Studies of telephonic case management showed no impact on preterm birth (Boehm 1996; Hodnett 2010; Lavender et al 2013)
- Review articles and meta-analyses of case management to prevent preterm birth using RNs, social workers, nutritionists, and other health professionals showed no impact on preterm birth (Lu 2010; Hodnett 2010)
- Different study methodology showed a reduction of preterm birth when members enrolled in CM early in pregnancy (by the end of the 2nd trimester) and when at least 3 to 8 face-to-face visits were completed by RNs and social workers (Roman 2013; Goyal 2013; possible selection bias)
- Practice-based “progesterone navigators” an important component of Ohio’s driver diagram and theory of change
Findings on low dose aspirin for preeclampsia prevention

- A randomized controlled trial of 1,620 women at high risk for preterm preeclampsia showed that using low dose aspirin significantly prevented preterm births (Rolnick 2017)
- ACOG recommends daily low dose aspirin between 12 and 28 weeks if:
  - history of early-onset preeclampsia and preterm delivery at less than 34 0/7 weeks of gestation
  - women with more than one prior pregnancy complicated by preeclampsia.
  - Multifetal gestation
  - Chronic hypertension
Findings on birth spacing

• Pregnancy intervals of $\leq$ 6 months between the previous delivery and last menstrual period of index pregnancy resulted in higher rates of preterm birth $<$34 weeks, compared to term births (Conde-Agudelo 2006; Rodrigues 2008)

• Interconception care is an opportunity for management of chronic disease risk between pregnancies
References


